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Porcine circovirus type 2 (PCV2) is the primary causative agent of postweaning multisystemic wasting
syndrome (PMWS) in pigs. To identify potential genetic determinants for virulence and replication, we serially
passaged a PCV2 isolate 120 times in PK-15 cells. The viruses harvested at virus passages 1 (VP1) and 120
(VP120) were biologically, genetically, and experimentally characterized. The PCV2 VP120 virus replicated in
PK-15 cells to a titer similar to that of the PK-15 cell line-derived nonpathogenic PCV1 but replicated more
efficiently than PCV2 VP1 with a difference of about 1 log unit in the titers. The complete genomic sequences
of viruses at passages 0, 30, 60, 90, and 120 were determined. After 120 passages, only two nucleotide mutations
were identified in the entire genome, and both were located in the capsid gene: the mutations were located at
nucleotide positions 328 (C328G) and 573 (A573C). The C328G mutation, in which a proline at position 110
of the capsid protein changed to an alanine (P110A), occurred at passage 30 and remained in the subsequent
passages. The second mutation, A573C, resulting in a change from an arginine to a serine at position 191
(R191S), appeared at passage 120. To experimentally characterize the VP120 virus, 31 specific-pathogen-free
pigs were randomly divided into three groups. Ten pigs in group 1 received phosphate-buffered saline as
negative controls. Each pig in group 2 (11 pigs) was inoculated intramuscularly and intranasally with 104.9 50%
tissue culture infective doses (TCID50) of PCV2 VP120. Each pig in group 3 (10 pigs) was similarly inoculated
with 104.9 TCID50 of PCV2 VP1. Viremia was detected in 9 of 10 pigs in the PCV2 VP1 group with a mean
duration of 3 weeks, but in only 4 of 11 pigs in the PCV2 VP120 group with a mean duration of 1.6 weeks. The
PCV2 genomic copy numbers in serum in the PCV2 VP1 group were significantly higher than those in the PCV2
VP120 group (P < 0.0001). Gross and histopathologic lesions in pigs inoculated with PCV2 VP1 were more
severe than those inoculated with PCV2 VP120 at both day 21 and 42 necropsies (P  0.0032 and P  0.0274,
respectively). Taken together, the results from this study indicated that the P110A and R191S mutations in the
capsid of PCV2 enhanced the growth ability of PCV2 in vitro and attenuated the virus in vivo. This finding has
important implications for PCV2 vaccine development.
Postweaning multisystemic wasting syndrome (PMWS) was
initially recognized in weaning piglets of a high-health-status
Canadian herd in 1991 (17). Since then, PMWS has become an
economically important disease in virtually all regions of the
world that produce pigs (3, 8, 10, 13, 23, 26). PMWS primarily
affects pigs between 5 and 18 weeks of age. Clinical PMWS
signs include progressive weight loss, dyspnea, tachypnea, ane-
mia, diarrhea, and jaundice (4, 11, 17). The primary causative
agent of PMWS has been identified as porcine circovirus type
2 (PCV2) (2–4, 8, 10–13, 18–21). Porcine circovirus type 1
(PCV1) was discovered as a noncytopathic contaminant of the
porcine kidney cell line PK-15 (30, 32) and is nonpathogenic to
pigs (1, 31).
Both PCV1 and PCV2 are small, nonenveloped viruses with
a single-stranded circular DNA genome of about 1.76 kb. The
PCV genome contains at least two functional open reading
frames (ORFs): ORF1 encodes the Rep proteins involved in
viral replication (7), and ORF2 encodes the immunogenic cap-
sid protein (7, 22, 25). PCV belongs to the Circoviridae family
along with chicken anemia virus, psittacine beak and feather
disease virus, and tentative members columbid circovirus,
goose circovirus, and canary circovirus (5, 24, 27, 33).
The complete genomic sequences of PMWS-associated
PCV2 and nonpathogenic PCV1 have been determined (13,
21). Sequence analyses revealed that PCV1 and PCV2 exhibit
about 75 or 76% nucleotide sequence identity and that their
genomes are organized similarly. We have previously demon-
strated that the PK-15 cell-derived PCV1 replicated more ef-
ficiently in PK-15 cells than PCV2 (15) and that PCV2 caused
characteristic PMWS pathological lesions in specific-pathogen-
free (SPF) pigs whereas PCV1 did not (12, 14–15). The genetic
determinants for PCV2 pathogenicity in pigs and for the en-
hanced growth ability of PCV1 in PK-15 cells are not known.
The objectives of this study are to identify the genetic de-
terminants for PCV2 virulence and replication. A pathogenic
PCV2 isolate was serially passaged in PK-15 cells 120 times,
and the viruses harvested from passages 1 and 120 were bio-
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logically, genetically, and experimentally characterized. We re-
port here that the passage 120 PCV2 virus replicated more
efficiently in PK-15 cells but was attenuated in experimentally
infected pigs. Two amino acid mutations identified in the cap-
sid gene are believed to be responsible for the increased
growth rate in vitro and for the attenuation in vivo.
MATERIALS AND METHODS
Virus and cell. The PCV1 virus used in this study was originally isolated from
a PK-15 cell line (ATCC CCL-33) (12). The PCV2 virus used in this study was
originally isolated from a spleen tissue sample from a pig with naturally occurring
PMWS (isolate 40895) (12, 13). The PK-15 cell line used in this study is free of
PCV1 contamination (12).
Serial passages of PCV2 in vitro. A homogenous PCV2 virus stock, designated
virus passage 1 (VP1), was generated by transfection of PK-15 cells with the
PCV2 infectious DNA clone as previously described (12). The VP1 PCV2 virus
stock was then serially passaged 120 times in PK-15 cells. Briefly, the infected
cells, when reaching confluency, were subcultured at a 1-to-3 ratio in minimum
essential medium containing Earle’s salts and L-glutamine supplemented with
2% fetal calf serum and 1 antibiotic (Invitrogen, Inc., Carlsbad, Calif.). Every
10 to 15 passages, the infected cells were harvested by freeze-thawing three times
and used to inoculate a new PK-15 culture. The newly infected culture was then
passaged 10 to 15 times by subculturing before repeating the freeze-thaw pro-
cedure. This procedure was repeated until virus passage 120 (VP120) was
reached. The virus harvested at each passage was stored at 80°C for further
analyses.
Biological characterization of PCV1, PCV2 VP1, and PCV2 VP120 viruses in
PK-15 cells. A one-step growth curve was performed to compare the growth
ability of PCV1, PCV2 VP1, and PCV2 VP120 in vitro. Briefly, PK-15 cells were
grown on six 12-well plates. The plates were infected, in duplicate, with PCV1,
PCV2 VP1, or PCV2 VP120 at a multiplicity of infection of 0.1, respectively.
After 1-h absorption, the inoculum was removed, and the cell monolayer was
washed five times with phosphate-buffered saline (PBS). Maintenance minimum
essential medium (2% bovine calf serum and 1 antibiotics) was subsequently
added to each well, and the infected cell cultures were continuously incubated at
37°C with 5% CO2. Every 12 h, the media and infected cells from duplicate wells
of each inoculated group were harvested and stored at 80°C until virus titra-
tion. The infectious titers of PCV1 and PCV2 viruses collected at different time
points were determined by immunofluorescence assays specific for PCV1 or
PCV2 as previously described (12, 15).
Genetic characterization of PCV2 viruses harvested at different passages. The
original PCV2 from a spleen tissue sample from a pig with PMWS (passage 0)
and PCV2 viruses from passages 30, 60, 90, and 120 were genetically character-
ized by determining the complete genomic sequences of the viruses from each
passage. Briefly, viral DNA was extracted from 100 l of the cell culture mate-
rials collected at different passages by using DNAzol reagent according to the
manufacturer’s protocol (Molecular Research Center, Cincinnati, Ohio). The
extracted DNA was resuspended in DNase-, RNase-, and proteinase-free water.
To amplify the entire genome, three pairs of PCV2-specific primers were used to
amplify three overlapping fragments: primer pair PCV2.2B (5-TCCGAAGAC
GAGCGCA-3) and PCV2.2A (5-GAAGTAATCCTCCGATAGAGAGC-3),
primer pair PCV2.3B (5-GTTACAAAGTTATCATCTAGAATAACAGC-3)
and PCV2.3A (5-ATTAGCGAACCCCTGGAG-3), and primer pair PCV2.4B
(5-AGAGACTAAAGGTGGAACTGTACC-3) and PCV2.4A (5-AGGGGG
GACCAACAAAAT-3). PCR was performed as follows: (i) 38 cycles, with 1
cycle consisting of denaturation (1 min at 94°C), annealing (30 s at 46°C), and
extension (2 min at 72°C); and (ii) a final extension step (7 min at 72°C). The
PCR products with the expected sizes were excised from 0.8% agarose gels,
purified by using a Geneclean kit (Bio 101, Inc., La Jolla, Calif.), and directly
sequenced for both strands using the PCR primers. The nucleotide and amino
acid sequences were compiled and analyzed with the MacVector program (Ox-
ford Molecular Ltd., Beaverton, Oreg.) using Clustal W alignment. The complete
sequence of PCV2 VP120 was compared to those of PCV2 VP0 and 91 other
PCV2 isolates as well as four PCV1 isolates available in the GenBank database.
Experimental characterization of PCV2 VP1 and serially passaged PCV2
VP120. To determine the pathogenic potential of VP120 PCV2, 31 SPF pigs that
were 3 to 4 weeks old were randomly assigned to three groups. Each treatment
group of pigs was housed in an individual room on raised wire decks. The air in
the rooms was changed 15 to 20 times per minute, and the temperature in the
rooms was maintained at approximately 72°F. Before inoculation, serum samples
from all piglets were tested by PCR for the presence of PCV1 or PCV2 DNA.
To maximize the efficiency of inoculation (14), each pig was inoculated with 1
ml of the inoculum intramuscularly and 3 ml intranasally. The 10 pigs in group
1 were each inoculated with PBS buffer as negative controls. Each pig in group
2 (11 pigs) received 104.9 50% tissue culture infective doses (TCID50) of PCV2
VP120, and each pig in group 3 (10 pigs) received 104.9 TCID50 of PCV2 VP1.
All pigs were monitored for clinical signs of disease. Serum samples were col-
lected from each pig at 1, 7, 14, 21, 28, 35, and 42 days postinoculation (dpi).
At 21 dpi, five randomly selected pigs from each group were necropsied. The
remaining pigs in each group were necropsied at 42 dpi.
Clinical evaluation. Pigs were weighed at 1, 7, 14, 21, 28, 35, and 42 dpi.
Rectal temperatures and clinical scores, ranging from 0 (normal) to 6 (severe)
(12), were recorded every other day from 0 to 42 dpi. Clinical observations,
including evidence of central nervous system disease, liver disease (icterus),
musculoskeletal disease, and changes in body condition, were recorded daily. A
team of two people performed clinical evaluations.
Gross pathology and histopathology. Complete necropsies were performed on
all pigs. The necropsy team was unaware of the inoculation status of the pigs. The
percentage of lung with grossly visible pneumonia was estimated for each pig
based on a previously described scoring system (12). Lesions such as the enlarge-
ment of the lymph nodes (ranging from 0 for normal to 3 for three times normal
size) were scored separately. Sections for histopathologic examination were
taken from the lungs (five sections) (12), heart, lymph nodes (tracheobronchial,
external iliac, mesenteric, mediastinal, and superficial inguinal), tonsil, liver,
thymus, spleen, small intestine, colon, and kidney. The tissues were examined by
individuals unaware of the inoculation status of the pigs and given a subjective
score for the severity of lung, lymph node, kidney, heart, and liver lesions (12).
Lung scores ranged from 0 (normal) to 4 (severe lymphohistiocytic interstitial
pneumonia). Liver scores ranged from 0 (normal) to 3 (severe lymphohistiocytic
interstitial hepatitis). Lymph node scores were an estimated amount of lymphoid
depletion and histiocytic replacement of follicles ranging from 0 (normal or no
lymphoid depletion) to 3 (severe lymphoid depletion and histiocytic replacement
of follicles) (12).
Serology. Blood samples were collected from all pigs at 1, 7, 14, 21, 28, 35,
and 42 dpi. Serum antibodies to PCV2 were detected by a modified indirect
enzyme-linked immunosorbent assay based on the recombinant ORF2 capsid
protein of PCV2 (25). Serum samples with a sample/positive (S/P) ratio of 0.2 or
greater were considered seropositive for PCV2.
Quantitative real-time PCR. Quantitative real-time PCR was performed to
determine the PCV2 virus loads in serum samples collected at 1, 7, 14, 21, 28,
35, and 42 dpi and in tracheobronchial lymph nodes collected during necropsies
at 21 and 42 dpi. Primer pair MCV1 (5-GCTGAACTTTTGAAAGTGAGCG
GG-3) and MCV2 (5-TCACACAGTCTCAGTAGATCATCCCA-3) (13) was
used for quantitative real-time PCR. PCR was performed in the presence of
intercalating SYBR green dye (Molecular Probes, Inc., Eugene, Oreg.) as pre-
viously described (14). A standard dilution series with a known amount of
pBluescript plasmid containing a single copy of the PCV2 genome (12) was run
simultaneously in each reaction mixture to quantify the virus genomic copy
number (14).
Immunohistochemistry (IHC). IHC detection of PCV2-specific antigen was
performed on formalin-fixed sections of lymph node, spleen, tonsil, and thymus
tissues collected during necropsy at 21 and 42 dpi as previously described (12, 14,
15). The amount of PCV2 antigen distributed in the lymphoid tissues was scored
by individuals unaware of the inoculation status of the pigs by assigning a score
of 0 for no signal to 3 for a strong positive signal (29).
Statistical analysis. All statistical analyses were performed using the SAS
system (version 8.02) (SAS Institute Inc., Cary, N.C.). Growth characteristics of
viruses were compared by linear regression analyses using the GLM procedure.
Serum samples S/P ratios were compared by analysis of variance, with the
MIXED procedure. The model included effects of inoculum, dpi, and their
interaction. S/P ratios were dichotomized to the presence or absence of sero-
conversion at a S/P ratio of 0.20 and analyzed by logistic regression using the
method of generalized equations in the SENROD procedure. Mean viral
genomic copy numbers in sera and lymph nodes of piglets in groups 2 and 3 were
compared by the Kruskal-Wallis test using the NPAR1WAY procedure and/or
analysis of variance of ranked data, followed by a Bonferroni test of multiple
mean ranks, using the GLM procedure. Serology and viremia data were analyzed
for all pigs up to 21 dpi, and these data were analyzed separately for the pigs
necropsied at 42 dpi. Clinical sign scores were dichotomized to the presence or
absence of clinical signs for each examination date and per pig over the entire
period of study and compared between groups by Fisher’s exact test using the
FREQ procedure, and by logistic regression using the LOGISTIC procedure.
Gross pathological and histopathologic scores were compared by the Kruskal-
Wallis test using the NPAR1WAY procedure and/or analysis of variance by using
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the GLM procedure, followed by a Bonferroni test of multiple means. The
proportions of pigs with gross and histopathologic lesions in various tissues in the
different groups of pigs were compared by Fisher’s exact test using the FREQ
procedure.
RESULTS
PCV2 VP120 replicated more efficiently in PK-15 cells than
the wild-type PCV2 VP1 did. To compare the growth charac-
teristics of nonpathogenic PCV1, wild-type PCV2 VP1, and
serially passaged PCV2 VP120, one-step growth curves were
performed in duplicate simultaneously for PCV1, PCV2 VP1,
and PCV2 VP120. The infectious titers of viruses collected at
12-h intervals were determined by immunofluorescence assays
(Fig. 1). The initial titers after infection at 12 h postinoculation
were about 101.5 TCID50/ml for all three viruses. The infec-
tious titers of PCV1 and PCV2 VP120 increased differently
than wild-type PCV2 VP1 did (P 0.0053) from 12 to 96 h. By
96 h postinfection, PCV1 and PCV2 VP120 had infectious
titers of 103.66 and 103.75 TCID50/ml, whereas PCV2 VP1 had
a titer of 102.83 TCID50/ml (Fig. 1).
Identification of two amino acid mutations within the PCV2
capsid protein during serial passages. The complete genomes
of the original wild-type PCV2 (VP0) and PCV2 passages 30,
60, 90, and 120 were amplified and sequenced. Sequence anal-
yses revealed that there were a total of two nucleotide muta-
tions, both in the capsid gene, at nucleotide positions 328
(C328G) and 573 (A573C) over the entire genome after 120
passages, and both resulted in amino acid changes. The C328G
mutation appeared at passage 30 in which a proline at amino
acid position 110 of the capsid was changed to an alanine
(P110A) (Fig. 2). This mutation was present during the re-
maining passages. A second mutation, A573C, resulting in an
amino acid change from arginine to serine at position 191 of
the capsid (R191S), was identified only at passage 120 (Fig. 2).
By comparing all known PCV1 and PCV2 sequences avail-
able in the GenBank database, including 91 PCV2 and 4 PCV1
isolates, we found that the P110A mutation is unique, as all
known PCV1 and PCV2 isolates have a proline at residue 110
of the capsid protein (Fig. 2). The R191S mutation, however, is
variable: most PCV2 isolates from North America have an
arginine, French PCV2 isolates and some Canadian PCV2
isolates have a glycine, and Spanish, Taiwanese, and German
PCV2 isolates have an alanine. All nonpathogenic PCV1 iso-
lates have a threonine residue at amino acid position 191 (Fig.
2). Overall, comparing the entire sequences of the capsid genes
of PCV1 and PCV2, extensive sequence variation was ob-
served: 33 to 35% of the nucleotides and 32 to 37% of the
amino acids varied (13).
PCV2 VP120 virus exhibited reduced duration of viremia
and virus loads in sera of infected pigs compared to those of
the wild-type PCV2 VP1 virus. Serum samples were collected
from all control and inoculated pigs at1, 7, 14, 21, 28, 35, and
42 dpi and assayed for PCV2 viremia by quantitative real-time
PCR and for anti-PCV2 antibody by enzyme-linked immu-
nosorbent assay. Prior to inoculation at 1 dpi, serum samples
from all pigs were tested and were negative for PCV2 DNA.
Group 1 (control) pigs were negative for PCV2 viremia
throughout the study (Table 1). PCV2 maternal antibodies in
pigs in group 1 were detected at 1 dpi, which decreased in all
pigs by 21 dpi. Seroconversion to PCV2 was not detected in
control pigs (Table 2).
FIG. 1. One-step growth curves of PCV1, PCV2 VP1, and PCV2
VP120. Duplicate synchronized PK-15 cell cultures were each infected
with PCV1, PCV2 VP1, or PCV2 VP120, all at an multiplicity of
infection of 0.1. All three viruses had a titer of about 101.5 TCID50/ml
at 12 h postinoculation. PCV1 and PCV2 VP120 replicated more
efficiently in vitro than did PCV2 VP1 (P  0.0053).
FIG. 2. Schematic diagram of amino acid mutations in the capsid
protein during serial passages of PCV2 in PK-15 cells. Serial passage
numbers are indicated (VP1, VP30, VP60, VP90, and VP120). Known
field isolates of PCV2 and PCV1 from different geographic origins are
also compared for these two mutations. US, United States.
TABLE 1. Detection of viremia in sera from inoculated and control pigs by real-time PCR
Group Inoculum
No. of pigs with viremia/no. testeda at dpi: Total no. of pigs
with viremia/no.
tested1 7 14 21 28 35 4
1 PBS buffer 0/10 0/10 0/10 0/10 0/5 0/5 0/5 0/10
2 PCV2 VP120 0/11 1/11 2/11 3/11 0/6 1/6 1/6 4/11
3 PCV2 VP1 0/10 7/10 8/10 8/10 3/5 3/5 1/5 9/10
a Five pigs from each group were necropsied at 21 dpi and the remaining pigs were necropsied at 42 dpi.
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In the group 2 pigs inoculated with PCV2 VP120, viremia
was first detected in 1 of 11 pigs at 7 dpi (Table 1 and Fig. 3).
A total of four pigs in group 2 were viremic during the study.
The average length of continuous viremia was 1.6 weeks. By 35
dpi, all group 2 pigs seroconverted to PCV2 (Table 2).
In the group 3 pigs inoculated with PCV2 VP1, viremia was
first detected in 7 of 10 pigs at 7 dpi (Table 1 and Fig. 3). Of
the 10 pigs in group 3, 9 became viremic during the study, and
the average length of continuous viremia was 3 weeks. All
animals in group 3 seroconverted to PCV2 by 35 dpi (Table 2).
The PCV2 genomic copy numbers per milliliter of serum in
positive samples ranged from 8,840 to 274,800 in group 2 pigs
inoculated with PCV2 VP120 and from 26,520 to 120,000,000
in group 3 pigs inoculated with PCV2 VP1 (Fig. 3). The PCV2
genomic copy numbers per milliliter of serum were greater in
group 3 pigs than in group 2 pigs at 21 dpi (P  0.0003) and 42
dpi (P  0.039). However, PCV2 DNA was detected in the
lymph nodes of only 3 of 11 group 2 pigs and 2 of 10 group 3
pigs, and the median PCV2 genomic copy numbers per milli-
gram of tracheobronchial lymph node did not differ in group 2
and 3 pigs (P  0.72). The virus recovered from the sera and
tracheobronchial lymph nodes of four selected pigs in groups 2
and 3 were sequenced, and sequence analyses revealed that the
viruses recovered from infected pigs originated from the re-
spective inocula.
The S/P ratios of PCV2 antibodies differed in the pigs of
groups 1, 2, and 3 (P  0.0001) and over time (P  0.0001).
PCV2 VP120 virus is attenuated in pigs. Mild sneezing and
rough hair coat were noted in some animals from all three
groups (data not shown). Two of the 10 control pigs and all of
the 21 inoculated pigs had sneezing and rough hair coat (P 
0.051). Up to 21 dpi, group 2 and 3 pigs were 58 (95% confi-
dence interval [95% CI], 13.1 to 255.0) and 41 (95% CI, 9.3 to
178.0) times more likely to show sneezing and rough hair coat
at any examination date than negative-control pigs, with no
difference between group 2 and 3 pigs (odds ratio for group 3
and 2 pigs [OR3vs2], 1.4 [95% CI, 0.8 to 2.6]). For the 16 pigs
that were necropsied at 42 dpi, over the entire study period,
again group 2 and 3 pigs were more likely to show sneezing and
rough hair coat than negative-control pigs (OR2vs1, 20.4 [95%
CI, 4.6 to 90.1]; OR3vs1, 71.6 [95% CI, 16.0 to 320.8]) with
group 3 pigs being 3.5 (95% CI, 1.9 to 6.6) times more likely to
show sneezing and rough hair coat than group 2 pigs. There
were no differences in weight gain (P  0.081) or mean rectal
temperatures (P  0.05) among any of the groups (data not
shown).
At necropsies, lymph nodes of two of five pigs in group 1
were mildly enlarged; however, this was not associated with
PCV2 infection, as evidenced by the lack of PCV2 DNA, PCV2
antigen, or seroconversion. At 42 dpi necropsy, all group 1 pigs
had normal lymph nodes (Table 3). Group 2 pigs inoculated
with PCV2 VP120 had mild to moderately enlarged lymph
nodes at both 21 and 42 dpi (Table 3). The lymph nodes in
group 3 pigs were moderately to severely enlarged at both 21
and 42 dpi (Table 3). Two pigs inoculated with PCV2 VP1 had
visible gross pneumonia at 21 dpi. Gross pneumonia was not
found in group 1 or 2 pigs at either 21 or 42 dpi.
FIG. 3. Quantitative real-time PCR results of PCV2 VP1 and PCV2 VP120 viral genomic copy numbers in 1 ml of serum sample collected at
1, 7, 14, 21, 28, 35, and 42 dpi from group 1, 2, and 3 pigs. Group 2 pigs inoculated with PCV2 VP120 that were positive for PCV2 DNA (Œ)
are indicated. The numbers inside the ‚ symbol on the x axis (10, 9, 8, 6, 5, and 5) are the numbers of pigs in group 2 that were negative for PCV2
viremia on the respective dpi. Group 3 pigs inoculated with PCV2 VP1 that were positive for PCV2 DNA (E) are indicated. The numbers inside
the E symbol on the x axis (3, 2, 2, 2, 2, and 4) are the numbers of pigs in group 3 that were negative for PCV2 viremia on the respective dpi. The
PCV2 genomic copy numbers are presented as the log of copy numbers per milliliter of serum (y axis).
TABLE 2. Seroconversion to PCV2 antibodies in pigs inoculated
with PCV2 VP1 and VP120
Group Inoculum
No. of pigs with PCV2 antibodies/no. testeda
at dpi:
1 7 14 21 28 35 42
1 PBS buffer 10/10b 1/10 1/10 0/10 0/5 0/5 0/5
2 PCV2 VP120 3/11b 0/11 0/11 0/11 0/6 6/6 6/6
3 PCV2 VP1 1/10b 0/10 1/10 2/10 4/5 5/5 5/5
a Five pigs from each group were necropsied at 21 dpi, and the remaining pigs
were necropsied at 42 dpi.
b Maternal antibodies were detected at 1 dpi but decreased in all groups
between 7 and 21 dpi.
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Microscopic lung lesions characterized by mild peribron-
chiolar lymphoplasmacytic and histiocytic bronchointerstitial
pneumonia and liver lesions characterized by mild lympho-
plasmacytic hepatitis were detected at variable levels in the
pigs of all groups (Table 4). The mean histological scores for
interstitial pneumonia in the lung, interstitial hepatitis in the
liver, and lymphoid depletion and histiocytic replacement for
lymph nodes, tonsils, and spleens are summarized in Table 4.
The presence of lesions in the kidney and heart is also pre-
sented in Table 4.
At necropsies (21 and 42 dpi), PCV2 antigen was not de-
tected by IHC in the lymphoid tissues of the negative-control
group 1 pigs. In group 2 pigs inoculated with PCV2 VP120, low
levels of PCV2 antigen were detected in spleen tissues of one
of five pigs at 21 dpi, in lymph node tissues of two of six pigs at
42 dpi, and in tonsil tissues of three of six pigs at 42 dpi (Table
5). In group 3 pigs inoculated with PCV2 VP1, low to high
levels of PCV2 antigen were detected in lymph node tissues of
five of five pigs, in tonsil tissues of four of five pigs, and in
spleen tissues of four of five pigs at 21 dpi. At 42 dpi, low to
moderate levels of PCV2 antigen were detected in group 3 pigs
inoculated with PCV2 VP1 (Table 5).
All gross pathological and histopathologic scores at 21 and
42 dpi were compared by analysis of variance using the GLM
procedure followed by a Bonferroni test of multiple means. At
21 dpi, the mean scores of group 1 and 2 pigs are similar (P 
1.00) but differ from the mean scores of group 3 pigs (P 
0.0032). By 42 dpi, the mean scores of group 1 differ from the
mean scores of group 2 (P 0.0083) and group 3 (P 0.0001),
and the group 2 mean scores are lower than those of group 3
(P  0.0274) (Tables 3 to 5).
DISCUSSION
PMWS associated with PCV2 infection has now become an
economically important global disease. The molecular mecha-
nisms of PCV2 replication and pathogenesis are poorly under-
stood. We report here the identification of two amino acid
mutations within the PCV2 capsid protein that are important
for PCV2 attenuation in vivo and for enhanced growth ability
in PK-15 cells.
PCV2 VP120 contained two amino acid mutations in the
capsid protein, P110A and R191S, compared to the wild-type
PCV2 parent virus (passage 0). As a result of these two mu-
tations, PCV2 VP120 replicated more efficiently (P  0.0053)
in PK-15 cells with a difference in infectious titer of about 1 log
unit compared to its parent virus. The difference in growth
ability with a 1-log-unit titer increase between VP120 and VP1
virus may be insignificant for many other viruses. However,
PCV is known to replicate to relatively low titers, usually below
105 TCID50 per ml, in PK-15 cells. PCV1 grows slightly better
than PCV2 (14–15), likely due to cell culture adaptation, since
PCV1 was originally isolated from PK-15 cells. PCV2 VP120
replicated to a similar level with the PK-15 cell-derived non-
pathogenic PCV1; thus, these two mutations either alone or
collectively are responsible for the enhanced growth ability of
TABLE 3. Gross lymph node and lung lesions in control and
inoculated pigs
Group Inoculum
No. of pigs with enlarged
lymph nodesa
No. of pigs with gross
pneumonia lesionsa
21 dpi 42 dpi 21 dpi 42 dpi
1 PBS buffer 2/5 (0.4) A 0/5 (0.0) A 0/5 (0.0) A 0/5 (0.0)
2 PCV2 VP120 2/5 (0.4) A 4/6 (1.3) B 0/6 (0.0) A 0/5 (0.0)
3 PCV2 VP1 5/5 (2.2) B 5/5 (2.6) B 2/5 (2.6) B 0/5 (0.0)
a Five pigs from each group were necropsied at 21 dpi, and the remaining pigs
were necropsied at 42 dpi. Values in parentheses are the mean scores of esti-
mated lymph node enlargement (scored from 0 [normal] to 3 [severely enlarged
and tan-colored lymph nodes]) and mean percentage of lungs affected by grossly
visible pneumonia (0 to 100%). Different letters (A and B) indicate statistically
different mean value score between groups (P  0.05).
TABLE 4. Distribution of histopathologic lesions in different tissues and organs from control and inoculated pigs
Group Inoculum dpi
No. of pigs with lesions/no. testeda
Lung
Lymph nodes Tonsil Spleen
Liver Kidney Heart
LD HR LD HR LD HR
1 PBS buffer 21 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 1/5 1/5
42 3/5 (0.6) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 0/5 (0.0) 1/5 (0.2) 1/5 0/5
2 PCV2 VP120 21 2/5 (0.4) 3/5 (0.6) 0/5 (0.0) 2/5 (0.4) 0/5 (0.0) 2/5 (0.4) 0/5 (0.0) 3/5 (0.6) 2/5 0/5
42 5/6 (1.0) 2/6 (0.3) 2/6 (0.3) 0/6 (0.0) 0/6 (0.0) 1/6 (0.2) 1/6 (0.2) 0/6 (0.0) 2/6 0.5
3 PCV2 VP1 21 2/5 (0.4) 4/5 (1.2) 3/5 (1.0) 5/5 (1.2) 1/5 (0.2) 4/5 (1.0) 4/5 (1.0) 3/5 (1.2) 3/5 3/5
42 5/5 (1.4) 5/5 (1.4) 3/5 (0.8) 0/5 (0.0) 1/5 (0.2) 4/5 (1.0) 3/5 (0.6) 3/6 (0.6) 1/5 2/5
a Values in parentheses are mean histological scores for interstitial pneumonia, interstitial hepatitis, and lymphoid depletion (LD) and histiocytic replacement (HR)
for lymph nodes, tonsils, and spleen. The severities of histopathologic lesions were significantly different (P  0.05 by Fisher’s exact test) for LD of lymph nodes at 42
dpi, LD of tonsils at 21 dpi, LD of spleen at 42 dpi, and HR of spleen at 21 dpi for groups 1, 2, and 3.
TABLE 5. IHC detection of PCV2 antigen in lymph nodes, tonsils,
and spleens of inoculated and control pigs
Group Inoculum dpi
No. of pigs with PCV2 antigen/no.
testeda
Lymph node Tonsil Spleen
1 PBS buffer 21 0/5 (0.0) 0/5 (0.0) 0/5 (0.0)
42 0/5 (0.0) 0/5 (0.0) 0/5 (0.0)
2 PCV2 VP120 21 0/5 (0.0) 0/5 (0.0) 1/5 (0.2)
42 2/6 (0.3) 3/6 (0.5) 0/6 (0.0)
3 PCV2 VP1 21 5/5 (1.6) 4/5 (1.0) 4/5 (1.2)
42 3/5 (0.8) 2/5 (0.4) 2/5 (0.4)
a Values in parentheses are the mean scores of the level of PCV2 antigen in
lymphoid tissues (scores ranged from 0 for no antigen detected to 3 for high
levels of antigen). The PCV2 antigen in lymph nodes and tonsils at 21 dpi were
significantly different (P  0.05 by Fisher’s exact test) in pigs from groups 1, 2,
and 3.
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PCV2 VP120 in vitro. Allan et al. (1) attempted to infect Vero
cells with PCV1. Intranuclear immune staining, characteristic
of PCV1 replication, was not detected until cell culture passage
6 in Vero cells. By passage 15, PCV1 replicated in Vero cells to
a level similar to that in PK-15 cells, suggesting that efficient
PCV1 replication in Vero cells depended upon the number of
virus passages. It would be interesting to see whether addi-
tional passages in PK-15 cells can further enhance the growth
ability of PCV2.
When SPF piglets were inoculated with PCV2 VP120, fewer
pigs developed viremia with shorter duration and lower PCV2
genomic copy numbers compared to pigs inoculated with
PCV2 VP1. We previously showed that the nonpathogenic
PK-15 cell-derived PCV1 also had a shorter mean viremia
length (0.625 week) in infected pigs (15). Seroconversion in the
absence of viremia has recently been demonstrated for an
attenuated chimeric PCV1-2 virus (14). Viremia was not de-
tected in pigs vaccinated with the chimeric PCV1-2 candidate
vaccine virus, even though the vaccinated pigs seroconverted
and were protected against challenge (14). Analyses of the
gross, microscopic, and IHC mean scores revealed that the pigs
inoculated with PCV2 VP120 virus had milder pathological
lesions than the pigs inoculated with PCV2 VP1 virus. These
results suggested that PCV2 VP 120 had adapted to grow
better in PK-15 cells and is attenuated in virulence in vivo.
After 120 passages in PK-15 cells, only two amino acid mu-
tations, both in the capsid gene, were detected in the entire
PCV2 genome, suggesting that the PCV2 genome is relatively
stable. This may explain why the sequences of all known PCV2
field isolates worldwide identified so far are highly conserved
(13, 21). The P110A mutation occurred early (passage 30)
during serial passage and involved two hydrophobic amino
acids, proline and alanine. The change from proline to alanine
may alter the tertiary structure of the capsid protein, as proline
is often involved in the bending regions of protein structures.
The uniqueness of the P110A mutation in passages 30 to 120
compared to the sequences of known PCV2 field isolates sug-
gested a biological role for this mutation. The fact that the
nonpathogenic PCV1 isolates have a proline (rather than ala-
nine) at this position complicated the potential implication of
this P110A mutation in PCV2 virulence. However, the exten-
sive sequence variation between the capsid proteins of PCV1
and PCV2 (32 to 37% amino acids differed) suggested that it
would be difficult to draw any conclusion on PCV2 virulence
based on sequence comparison with the capsid protein of the
nonpathogenic PCV1. The R191S mutation occurred very late
during the serial passage (between passages 91 and 120) and is
unique to the VP120 PCV2 virus, as all known PCV2 and
PCV1 sequences so far do not have a serine residue at this
position. However, glycine, alanine, and threonine substitu-
tions at this position were found in field isolates of PCV1 and
PCV2. Lekcharoensuk et al. (22) identified at least two con-
formational neutralizing epitopes in the PCV2 capsid protein,
and the R191S mutation falls within one of these immunore-
active epitopes, suggesting that the R191S mutation may play
an important role in PCV2 replication and pathogenesis. Ter-
tiary structure changes as the results of these two amino acid
mutations in the capsid protein could drastically influence its
biological functions. Crystallization of the capsid protein to
determine the three-dimensional structure could provide clues
regarding the effects of these amino acid mutations on virus
structure.
Amino acid substitutions induced by cell culture passage or
chemical mutagenesis techniques have been routinely used for
the attenuation of many viruses and have led to the production
of numerous vaccines (6). There are many examples of a single
amino acid mutation leading to the attenuation of a virus. For
example, a single amino acid change in the VP3 capsid of
poliovirus Sabin type 3 strain (35) and two changes in the
chicken infectious bursal disease virus VP2 capsid were re-
sponsible for the acquisition of attenuated phenotypes (34). A
single amino acid change in the rabies virus envelope glyco-
protein (9) and three changes in Sindbis virus E1 and E2
proteins (28) also led to virus attenuation. It has also been
shown that substitution of proline for leucine at residue 101 of
the nonstructural 4B protein of the mosquito-borne dengue 4
virus resulted in decreased viral replication in mosquitoes but
increased replication in Vero cells (16). Hence, the balancing
control of efficient replication of dengue 4 virus in either mos-
quito or Vero cells was maintained by a single amino acid
change. Within the Circoviridae family, a single amino acid
mutation in the VP1 capsid protein of chicken anemia virus
was found to be responsible for the pathogenicity of the virus
in chickens (36). Taken together, the results from this study
suggested that the P110A and R191S mutations are likely re-
sponsible for the attenuation of PCV2 VP120 in pigs and for
the enhanced growth ability of PCV2 in PK-15 cells. Addi-
tional studies are under way to determine whether the two
mutations act singly or collectively in modifying the PCV2
phenotype.
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